TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05917379

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fecal microbiota
Description: FMT utilizes stool from a healthy donor and puts them into capsules after processing

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fecal microbiota
Description: FMT utilizes stool from a healthy donor and puts them into capsules after processing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Starch into the same outlook capsule with fecal microbiota

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch into the same outlook capsule with fecal microbiota

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch into the same outlook capsule with fecal microbiota

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: synbiotics
Description: Lactobacillus Helveticas+ Bifidobacterial longum + inulin(3g/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: synbiotics
Description: Lactobacillus Helveticas+ Bifidobacterial longum + inulin(3g/day)
Study: NCT06208709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: carpal arch space augmentation (CASA)
Description: A BOA brace with a balloon that is affixed internally. The device applies a small cyclic force of to the wrist. The cycles include a brief period of force applied, followed by a brief period of no force. The device is intended to be worn during hours of sleep.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard of care (SOC)
Description: A BOA brace that can be adjusted to the arm of the participant.
Study: NCT06055699

Intervention type: OTHER
Intervention: Fecal sampling
Description: Stool samples are a collection of products derived from the human body that is not invasive in any way and samples not taken as part of usual care.~Stool samples will be collected at home within 7 days of the visit M0, M3 and M6 and within 14 days of the visit M12 in an ethanol tube and in DNA/RNA shield, and transported at room temperature to Saint-Antoine Hospital (CRB SAT, AP-HP, Pr. SIMON ), samples will be aliquoted (3 aliquots per tubes) and stored at -80°C for a period of 5 years (renewable) At the end of the research, stool samples will be analysed using metagenomics sequencing.~DNA extraction will be performed following the standards of the The International Human Microbiome Standards . DNA will be stored at -80°C.

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood samples (serum, 15 ml) are an additional and minimal collection performed following a sample taken as part of usual care.~Blood samples (serum) will be collected during the visit at M0, M3 (± 7 days), M6 (± 7 days) and M12 (± 7 days).~In the hours following collection, the samples must be aliquoted and stored at -80°C in a secure place in the participating centre.
Study: NCT04072640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole 200mg
Description: Induction treatment with voriconazole( 400mg/d)+5FC (100mg/kg/d) for 14 days;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amphotericin B deoxycholate (0.4-0.5mg/kg/d)
Description: Induction treatment with 0.4-0.5mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amphotericin B-deoxycholate (0.7-1.0mg/kg/d)
Description: Induction treatment with 0.7-1.0mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 14 days
Study: NCT05441345

Intervention type: OTHER
Intervention: questionnaires with collection of stool and urine
Description: questionnaires will be completed (GPAQ, SarQoL, EQ-5D-3L, SF36), with collection of stool (for care and research) and urine
Study: NCT04442581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04275752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Perform endurance (treadmill or cycle ergometer), strength (weight resistance), and flexibility training twice a week for a period of one hour per session, for a total of 16 sessions.
Study: NCT06128512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Description: Auricular acupuncture is administered 24 hours before the examination using patches, each possessing a square shape with a side length of 10 mm, coupled with a sterilized needle measuring 0.25 x 1.3 mm. Four acupoints are selected on one ear, including the Master cerebral point, Tranquilizer point, Relaxation point, and Heart point (CO15). The patch containing the needle will remain in place until the student completes the examination.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Auricular acupuncture
Description: Sham Auricular acupuncture is administered 24 hours before the examination using patches, each possessing a square shape with a side length of 10 mm, without a needle. Four acupoints are selected on one ear, including the Master cerebral point, Tranquilizer point, Relaxation point, and Heart point (CO15). The patch will remain in place until the student completes the examination.
Study: NCT05604105

Intervention type: OTHER
Intervention: Questionnaire
Description: The questionnaire includes a section for socio-demographic data, a section to detect their general awareness of oral cancer as a disease, a section about their awareness of its signs and symptoms and lastly, a section about its risk factors and habits.
Study: NCT04309721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Single-dose of Perampanel 12 mg film-coated tablet, will be given orally in patients with status epilepticus that do not involve the oral and pharyngeal musculatures. In alternative, perampanel will be administered by a nasogastric feeding tube, a procedure which has been recently reported to be safe and tolerated in patients with generalised status epilepticus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single-dose of placebo of Perampanel, administered orally. Placebo of perampanel will be given orally, in patients with status epilepticus that do not involve the oral and pharyngeal musculatures. In alternative, Placebo of perampanel will be administered by a nasogastric feeding tube, a procedure which has been recently reported to be safe and tolerated in patients with generalised status epilepticus
Study: NCT06781762

Intervention type: OTHER
Intervention: N/A (Usual Care)
Description: BC survivors will be using aromatase inhibitors as prescribed in their usual care treatment.
Study: NCT06780826

Intervention type: DRUG
Intervention: Atezolizumab
Description: Atezolizumab, 1200 mg intravenous infusion, 21 days per cycle

Intervention type: DRUG
Intervention: Etoposide
Description: Etoposide,intravenous infusion, 100mg/m,21 days per cycle

Intervention type: DRUG
Intervention: Etoposide
Description: Etoposide,intravenous infusion, 100mg/m,21 days per cycle

Intervention type: DRUG
Intervention: Carboplatin
Description: carboplatin,intravenous infusion, AUC=5, 21 days per cycle.

Intervention type: DRUG
Intervention: Carboplatin
Description: carboplatin,intravenous infusion, AUC=5, 21 days per cycle.
Study: NCT06780163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17β-estradiol 10 mcg
Description: 17β-estradiol 10 mcg will be given to all participants. The participants will be asked to use 1 tab daily for 2 weeks vaginally before bed, then 1 tab twice a week vaginally before bed until 12 weeks
Study: NCT06780358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI supported detection of bladder cancer
Description: AI-model-supported detection of bladder cancer during white light cystoscopy
Study: NCT05795660

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: platelet rich plasma
Description: platelet rich plasma injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: platelet rich plasma injection
Study: NCT05698992

Intervention type: OTHER
Intervention: evidence-based individualized rehabilitation
Description: The experimental group will receive structured individualized assessment based on physical, psychological or social needs and will be offered evidence-based interventions to promote rehabilitation and recovery.
Study: NCT06488222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Subjects will receive 40 mg docetaxel intravesically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Subjects will receive 1 mg gemcitabine intravesically.
Study: NCT04747626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B-SAFER
Description: Simplified hybrid frozen elephant trunk repair will be performed by utilizing B-SAFER technique which involves a physician modified endovascular stentgraft to treat the proximal aorta in subjects with aortic disease involving multiple segments.
Study: NCT05566054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide 10mg orally daily for 7 days (d1-d7)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: azacytidine 75mg/m2 daily for 7 days (d1-d7)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: azacytidine 75mg/m2 daily for 7 days (d1-d7)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28)
Study: NCT04907604

Intervention type: DEVICE
Group type: OTHER
Intervention: A multi-modal and integrative e-health platform aimed at promoting health and reducing the negative impact of mental problems in the workplace
Description: It addresses six main domains: improving awareness of mental health problems and reducing stigma; reducing psychosocial risk factors in the workplace; improving wellbeing and reducing psychological symptoms; ensuring early detection of mental disorders; promoting healthy behaviours and lifestyles; and facilitating early return to work.

Intervention type: DEVICE
Group type: OTHER
Intervention: A multi-modal and integrative e-health platform aimed at promoting health and reducing the negative impact of mental problems in the workplace
Description: It addresses six main domains: improving awareness of mental health problems and reducing stigma; reducing psychosocial risk factors in the workplace; improving wellbeing and reducing psychological symptoms; ensuring early detection of mental disorders; promoting healthy behaviours and lifestyles; and facilitating early return to work.

Intervention type: DEVICE
Group type: OTHER
Intervention: A multi-modal and integrative e-health platform aimed at promoting health and reducing the negative impact of mental problems in the workplace
Description: It addresses six main domains: improving awareness of mental health problems and reducing stigma; reducing psychosocial risk factors in the workplace; improving wellbeing and reducing psychological symptoms; ensuring early detection of mental disorders; promoting healthy behaviours and lifestyles; and facilitating early return to work.
Study: NCT05151744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamikibart
Description: Vamikibart will be administered by IVT injection in the study eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab will be administered by IVT injection in the study eye.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab will be administered by IVT injection in the study eye.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Procedure
Description: Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye.
Study: NCT06447181

Intervention type: DEVICE
Intervention: 3D visualization technology ; ICG fluorescence technology .
Description: Three-dimensional reconstruction technology is a software that can collect CT and MRI data, perform image segmentation and three-dimensional reconstruction of the liver, gallbladder, dilated bile ducts, pancreas, venous, and arterial systems step by step.~ICG fluorescence technology is a fluorescent laparoscopic technology that can detect extrahepatic biliary duct misalignment, improving surgical precision and safety.
Study: NCT05247580

Intervention type: OTHER
Intervention: Hicks self-confidence scale, Karasek survey, Maslach Burnout Inventory
Description: Questionnaires (Hicks self-confidence scale, Karasek questionnaire, Maslach Burnout Inventory) sent to hospital staff caregivers before and after (at 3 and 6 months) their SUrVIS training.
Study: NCT05649358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lactate sensor (Lactisense)
Description: Non-invasive monitoring of interstitial lactate levels during and after exercise.
Study: NCT04309773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy
Description: Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy Treatment duration : 24 months Bezafibrate/AUDC : daily oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Bezafibrate in addition to standard UDCA therapy
Description: Placebo of Bezafibrate (400mg) in addition to standard 15-20 mg/kg/Day UDCA therapy Treatment duration : 24 months Placebo/AUDC : daily oral dose
Study: NCT06781099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-volume continuous veno-venous haemodialysis with MEX-CD1 use
Description: MEX-CD1 is a hyper-chelating colloidal solution that can be added to the dialysate to be used in low-volume continuous veno-venous hemodialysis. Intervention includes 3 low-volume continuous veno-venous hemodialysis for a duration of 4 hours each. For non-hospitalized patients, the treatment is performed on an outpatient basis.
Study: NCT06781970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Vitamin C
Description: Patients will be given 500 mg of oral vitamin C, tid, for 7 days prior to phacoemulsification and 4 weeks after phacoemulsification

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Vitamin C
Description: Patients will be given 500 mg of oral vitamin C, tid, for 7 days prior to phacoemulsification and 4 weeks after phacoemulsification

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be given placebo, tid, for 7 days prior to phacoemulsification and 4 weeks after phacoemulsification

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will be given placebo, tid, for 7 days prior to phacoemulsification and 4 weeks after phacoemulsification
Study: NCT06782178

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic lysis and lavage
Description: Arthroscopic lysis and lavage refers to an arthroscopic procedure where the temporomandibular joint is rinsed with saline solution and where the joint capsule is distended and where adhesions are lysated bluntly.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrocentesis/Saline
Description: Arthrocentesis refers to a blind irrigation of the temproromandibular joint with saline solution
Study: NCT06779851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPT567
Description: Immunocytokine infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPT567
Description: Immunocytokine infusion
Study: NCT06097936

Intervention type: DIAGNOSTIC_TEST
Intervention: HPV-ASSOCIATED OROPHARYNGEAL CANCER
Description: The study involves the coexistence of a retrospective part, in which a group of patients with HPV-associated OPC for whom follow-up data of at least 2 years after diagnosis are available, designed in order to evaluate the expression of HPV16-specific E5 transcript as well as that of pEGFR and HLA, and a multicenter prospective part, involving the enrollment of a control group, enrolled at the ENT outpatient clinic of the IRE and the outpatient clinics of the relevant LILT provincial committees, to better elucidate the role of HPV16-E5 in identifying potentially transforming infections due to the presence of HPV.
Study: NCT06780904

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling
Description: Treatment protocol:~1. Dry needling: Prone position, identify trigger points in upper trapezius, use Hong technique with 50mm/0.25 gauge needle, eliciting local twitch response.~2. Passive stretching: Supine position, cervical spine stretched just short of restriction, hold for 30s with 20s rest, repeat 3 times.~3. Muscle Energy Technique: Supine position, identify restriction barrier, move spine away from barrier, instruct patient to isometrically contract opposing movement (25% strength), hold for 7-10s, then stretch towards new barrier for 30s, repeat 3 times.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dry Needling
Description: Treatment protocol:~1. Dry needling: Prone position, identify trigger points in upper trapezius, use Hong technique with 50mm/0.25 gauge needle, eliciting local twitch response.~2. Passive stretching: Supine position, cervical spine stretched just short of restriction, hold for 30s with 20s rest, repeat 3 times.~3. Muscle Energy Technique: Supine position, identify restriction barrier, move spine away from barrier, instruct patient to isometrically contract opposing movement (25% strength), hold for 7-10s, then stretch towards new barrier for 30s, repeat 3 times.
Study: NCT06779929

Intervention type: DRUG
Intervention: Tirzepatide
Description: Tirzepatide

Intervention type: DRUG
Intervention: Dulaglutide
Description: Dulaglutide
Study: NCT06780865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment with Arotinolol or Amlodipine or Clonidine
Description: Participants will receive Almar 10 mg orally once daily between 8:00 PM and midnight. At the subsequent visit, if nocturnal blood pressure remains above the target of \<120/70 mmHg, Amlodipine Besylate will be added at a dose of 2.5 mg to 5 mg orally once daily. Should nocturnal blood pressure still not achieve the target at the following visit, Clonidine Hydrochloride 75 µg will be added to the regimen. The target for nocturnal blood pressure control is set at \<120/70 mmHg. For participants whose clinic blood pressure exceeds 140/90 mmHg, an unscheduled visit will be arranged within one month. If elevated clinic blood pressure persists during this visit, a 24-hour Ambulatory Blood Pressure Monitoring (ABPM) will be conducted. If the ABPM results indicate daytime blood pressure ≥135/85 mmHg, open-label add-on antihypertensive therapy will be initiated, prioritizing the use of antihypertensive medications outside of the study drugs to achieve blood pressure control.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-controlled group
Description: Participants are treated with corresponding placebo
Study: NCT03474718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-rich Plasma Left Side
Description: Group A will receive PRP on left side of scalp and placebo (saline solution) on right side of scalp.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-rich Plasma Right Side
Description: Group B will receive PRP on right side of scalp and placebo (saline solution) on left side of scalp.
Study: NCT06569537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine topical
Description: 4%
Study: NCT06781619

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test Product: Plant based high energy high protein ONS
Description: Plant based high energy high protein ONS 2 servings/day for a period of 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Product: Dairy based high energy high protein ONS
Description: Dairy based high energy high protein ONS 2 servings equivalent in energy \& protein for a period of 8 weeks.
Study: NCT05777759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Lyft with Lidocaine
Description: hyaluronic acid

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvederm Voluma XC
Description: hyaluronic acid
Study: NCT05173818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen at 1.5 ATA
Description: Hyperbaric oxygen (HBO2) at 1.5 ATA (active) group (hyperbaric oxygen-chamber compressed to 1.5 atmosphere absolute and breathing \>99.9% oxygen). Each participant should complete 40 sessions, one session per day, five per week over the course of 3 months.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Sham treatment includes pressurizing the chamber to 1.2 ATA with air for 5 minutes with noise of circulating air, return the chamber to 1.0 ATA after 5-7 minutes and maintain it at that pressure for until the end of the treatment, with noise of circulating air. Internal control knobs will be concealed. Participants will be instructed to undergo intermittent ear clearing technique during the initial 5 minutes of descent
Study: NCT06569537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLT
Description: Topical Benzocaine 20%/ Lidocaine 8%/Tetracaine 4%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLT
Description: Topical Benzocaine 20%/ Lidocaine 8%/Tetracaine 4%
Study: NCT04874038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 20mg/ml
Description: Patients in the intervention group will receive an IV lidocaine infusion using a dosage regimen of 1.5 mg/kg bolus of a 2% lidocaine solution with induction of general anesthesia followed by a 2.0 mg/kg/hour infusion until the end of surgery (and up to 30 minutes into recovery room).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the control group will receive a placebo bolus and infusion with normal saline (0.9% sodium chloride solution) until the end of surgery (and up to 30 minutes into recovery room).
Study: NCT04649710

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days